Algernon Pharmaceuticals is a clinical stage pharmaceutical development company focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease , idiopathic pulmonary fibrosis and chronic cough.In August 2018, Breathtec Biomedical signed a Letter of Intent to acquire 100% of the shares of Nash Pharmaceuticals Inc. In October 2018, Breathtec signed a definitive agreement with Nash to acquire all of the issued and outstanding securities of the company, under which Breathtec would issue an aggregate of 15,800,000 common shares to the holders of Nash Pharma common shares at a deemed price of CAD $0.311(US $0.24) per payment share. In addition, at closing of all outstanding unexercised warrants to acquire Nash Pharma common shares pursuant to outstanding Nash Pharma warrants would be cancelled. In consideration for such disposition, the holders of Nash Pharma warrants would receive the right (a "Replacement Warrant")